There are exceptions to this survival duration range, as exemplified by a case report from Marinova et al., demonstrating that a 43-year-old patient with BRAF-positive stage IIIa melanoma was responsive to radiation and immunotherapy. The gene discussed is BRAF; the disease is melanoma.